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effects on normal tissue: subjective, objective, management 
tool (LENT/SOM) was an endpoint.
Results Two symptom clusters were identified (urinary 
cluster and sexual cluster). The grouping of symptom clus-
ters was different than UCLA-PCI Scales. Two items of 
the urinary function scales (“number of pads” and “urinary 
leak interfering with sex”) were excluded from the urinary 
cluster. The correlation with the other items in the scale 
ranged from 0.20 to 0.21 and 0.31 to 0.39, respectively. 
Cronbach’s Alpha showed low correlation of those items 
with the Urinary Function Scale (0.14–0.36 and 0.33–0.44, 
respectively). All urinary function scale items were subject 
to a ceiling effect. Clusters had better predictive accuracy, 
AUC = 0.70 –0.65, while scales AUC = 0.67–0.61.
Conclusion This study adds to the knowledge on how 
cluster analysis can be applied for the interpretation and 
utilisation of PROMs. We conclude that multiple-item 
scales should be evaluated and that symptom clusters pro-
vide a study-specific approach for modelling and interpre-
tation of PROMs.
Keywords Symptom clusters · UCLA-PCI · Urinary 
symptoms · PROMs analysis · Summative scores
Introduction
Patient reported outcome measures (PROMs) are health 
questionnaires that are completed directly by patients to 
measure patients’ health status or health-related quality of 
life (HRQOL). In radiotherapy, PROMs are used to obtain 
an insight into patients’ perceptions of the impact of their 
cancer and the consequences of treatment [1]. The advan-
tage of PROMs over other patient monitoring techniques 
is that they provide information as perceived by patients. 
Abstract 
Purpose To investigate the role of symptom clusters in 
the analysis and utilisation of patient reported outcome 
measures (PROMs) for data modelling and clinical prac-
tice. To compare symptom clusters with scales, and to 
explore their value in PROMs interpretation and symptom 
management.
Methods A dataset called RT01 (ISCRTN47772397) 
of 843 prostate cancer patients was used. PROMs were 
reported with the University of California, Los Angeles 
Prostate Cancer Index (UCLA-PCI). Symptom clusters 
were explored with hierarchical cluster analysis (HCA) and 
average linkage method (correlation > 0.6). The reliability 
of the Urinary Function Scale was evaluated with Cron-
bach’s Alpha. The strength of the relationship between the 
items was investigated with Spearman’s correlation. Pre-
dictive accuracy of the clusters was compared to the scales 
by receiver operating characteristic (ROC) analysis. Pres-
ence of urinary symptoms at 3 years measured with the late 
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Therefore, PROMs add an important dimension to the 
information gathered by professional assessments or clini-
cal tests. The patient’s perspective provides a holistic and 
a more comprehensive assessment of the treatment and 
PROMs are increasingly being seen as a way to improve 
practice by enhancing communication, improving manage-
ment of symptoms associated with cancer or treatment as 
well as identifying patient care needs.
With significant improvements in rates of long-term 
survival [2], longitudinal PROMs in prostate cancer play a 
particularly important role as they offer the ability to assess 
and address health concerns or HRQOL issues of individ-
ual patients [3–5]. Other important clinical applications of 
PROMs include aiding treatment choices as well as identi-
fying high-risk cancer patients, to achieve the best possible 
long-term health-related outcomes [6, 7]. These are all key 
challenges of modern oncology and PROMs play a strate-
gic role in this as they enable tailored treatments and out-
comes according to priorities, risks or concerns of individ-
ual patients [8, 9]. However, the successful application of 
PROMs in this area requires a deeper understanding of the 
methods for extracting information carried within PROMs 
[1]. PROMs data are complex, with large number of varia-
bles (HRQOL, symptoms, function, bother, performance or 
heath concerns) measured on different scales (with differ-
ent levels, ratios or frequencies) and with confounders that 
can be attributed to cancer treatment or individual patient 
characteristics.
To extract and interpret information contained within 
PROMs summative scores are used (individual items are usu-
ally pooled together using average scores, or less commonly 
using the highest score). In tools such as the University of 
California, Los Angeles Prostate Cancer Index (UCLA-PCI), 
items are arranged in scales according to the underlying func-
tion or health concern. These scales are developed and care-
fully validated using clinical data [10, 11], and they are used 
to create agglomerate scores [11, 12]. However, this generic 
approach of summarising PROMs may become less sensitive 
or less specific for new treatments or changing patient popu-
lations. It has been shown that different treatments or patient 
populations (with different recruitment factors such as age or 
baseline characteristics) can generate different symptom pro-
files or symptom prevalence [13–16]. An alternative method 
of grouping symptoms for the purpose of extracting mean-
ingful information and utilisation of PROMs in data model-
ling or clinical decision making is to use symptom clusters. 
Symptom clusters are groups of 3 or more correlated symp-
toms that occur together, and this is stable over time [17, 
18]. The advantage of exploring symptom clusters within a 
dataset is that it allows a study-specific method of grouping 
symptoms, as symptom clusters can be easily determined 
specifically to each dataset or clinical trial. With that symp-
tom, clusters have the potential to improve sensitivity and 
specificity to symptom grouping. Only items that are strongly 
correlated, and so measure the same underlying health con-
cern, are included in summative scores.
The concept of symptom clusters is well known, and the 
methodology to define symptom clusters within PROMs 
data is well established [19–21]. The idea behind utilising 
symptom clusters in data modelling or symptom manage-
ment is that symptoms in clusters are concurrent, and exert 
influence on one another. Symptom clusters were shown to 
be beneficial in providing effective symptom management 
in chemotherapy cancer patients (with various cancers) [22], 
and for determining multiple-symptom management strat-
egies in cancer nursing [23]. It has been shown in HRQOL 
studies that managing symptoms in isolation is not as effec-
tive as managing symptoms in clusters [24–27]. This may be 
explained by common mechanisms of occurrence or com-
mon aetiology of symptoms in clusters [18, 28]. However, 
the relationship between symptoms in clusters is not yet fully 
understood.
We hypothesised that the study-specific grouping of 
PROMs items using symptom clusters provides a more sen-
sitive and specific approach for the analysis of PROMs than 
the generic tool’s scales. Symptom clusters have the potential 
to identify patients at high risk of symptoms or side effects 
more accurately. This is because they allow for the grouping 
of items and calculating composite scores from items that are 
highly correlated, so they exhibit similar prevalence and are 
present in the same patients. In contrast, scales group symp-
toms according to the predefined disease and treatment-spe-
cific function or bother. This is important because of the pos-
sibility that trends or prevalence of symptoms for the same 
scale may vary from study to study, for example, according 
to the treatment modality or patient population. Radiotherapy 
prostate cancer patients experience different symptoms than 
those that have undergone prostatectomy [16, 28]. With the 
generic approach using scales for summarising PROMs, 
items that have different prevalence or trends in a study popu-
lation will be included in the average score [29]. This may 
result in the loss of sensitivity in identifying patients at high 
risk of symptoms, or in alerts being created for patients with 
high symptoms that are not related to the same underlying 
health concern leading to loss of specificity. Therefore, symp-
tom clusters have the potential to allow more meaningful 
PROMs data analysis and interpretation as symptom group-
ing can be calculated in a way that is unique to each study.
Materials and methods
Dataset and PROMs tool
In this study, we used MRC RT01 (ISCRTN47772397), 
a dataset consisting of 843 prostate cancer patients in a 
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randomised controlled trial coordinated for the UK Medical 
Research Council (MRC) [30, 31]. MRC RT01 was a large, 
multicentre UK trial of patients with localised prostate 
cancer. Patients were randomly assigned to standard-dose 
(64 Gy) or escalated-dose (74 Gy) conformal radiotherapy 
(CFRT), which were both administered with neoadjuvant 
androgen suppression [32–35]. PROMs data were col-
lected longitudinally with the UCLA-PCI. Data were gath-
ered from the study cohort at ten time points (pre-hormone 
therapy, pre-radiotherapy, week 10, month 6, 12, 18, year 
2, 3, 4 and 5 after the start of radiotherapy). The numbers 
of completed UCLA-PCI questionnaires at each point in 
time were 578, 757, 738, 712, 689, 655, 645, 594, 515 and 
425, respectively. UCLA-PCI includes 20 items measur-
ing six scales of function and bother in the three primary 
prostate cancer concern areas (urinary, bowel and sexual) 
[10]. To demonstrate the concepts presented in this study, 
we focused on the urinary domain of health (presented in 
the Appendix, Fig. 4). There are two scales (function and 
bother) in UCLA-PCI urinary domain. These are a five-
item urinary function scale (“urinary leak”, “urinary con-
trol”, “dripping/wetting”, “number of pads” and “urinary 
leak interfering with sex”) and a single-item urinary bother 
scale (“How big a problem has urinary function been”; 
referred throughout as “urinary bother”).
The endpoint for statistical modelling and prediction 
was the measurement of late urinary symptoms at year 3 
using the physician completed grading tool: late effects 
on normal tissue: subjective, objective, management tool 
(LENT/SOM) [36]. The aim of the analysis was to compare 
the predictive power of the urinary cluster to the urinary 
function scale. Literature has shown that early symptoms 
are often a precursor of late symptoms [37]. A binary vari-
able of LENT/SOM recording any bladder or urethra symp-
toms (yes or no) was used. Data at year 3 were available 
for 725 patients. Data from year 3 post-radiotherapy were 
used because this post-treatment period has been shown to 
be representative of late urinary symptoms [30, 38]. While 
early side effects develop during radiotherapy and usually 
improve within the first few months after treatment, late 
side effects emerge months after radiotherapy, continue to 
develop post-treatment [39, 40] and usually get worse over 
subsequent years [38, 41]. Year 3 was used rather than 
years 4 or 5 due to the increasing number of drop-outs after 
3  years. In year 4, the number of completed LENT/SOM 
questionnaires decreased to 621 and again in year 5 to 521.
Data pre‑treatment and missing data
Data analysis was performed at each time point for patients 
that completed their UCLA-PCI questionnaires in the 
respective time window. Intermittent missing data were 
treated with multiple imputation using seven imputations. 
Multiple imputation was used rather than complete case 
analysis in order to minimise the risk of biased results and 
to preserve sample size [42–44]. Although five imputations 
are recommended in theory as being sufficient [45], seven 
imputed datasets were created to further reduce uncertainty 
in the prediction of missing values from the imputation 
process [46, 47]. Clustering analysis was also performed on 
complete cases and the results were identical. The results of 
exploratory data analysis looking at prevalence of urinary 
domain items were shown for complete cases. The num-
ber of missing data is also indicated. In addition to treating 
missing data, variables were also rescaled to correct for the 
difference in scales. Variables were recorded on a Likert 
scale with levels from 3 to 6 so they were rescaled from 0 
to 100 as recommended by the scoring manual [12] so that 
they have the same impact on the analysis. Variables that 
were negatively worded were reversed.
Symptom clustering
Clustering of patient-reported symptoms from the UCLA-
PCI was performed at ten points in time. The similarity 
between symptoms was measured with Spearman’s rho 
correlation coefficient (rs) [48]. To obtain pooled results 
from seven multiple imputed datasets, composite corre-
lation matrices were calculated for each time point using 
Fisher’s z transformation [49, 50]. Clustering between the 
symptoms was identified using hierarchical cluster analysis 
(HCA) with average linkage method of cluster agglomera-
tion. Symptom clusters were determined at a cut-off corre-
lation value of >0.6 [19, 20].
Strength of the association between symptoms 
in the urinary function scale
To measure the reliability of the UCLA-PCI urinary func-
tion scale, Cronbach’s alpha was used [51]. This is a sta-
tistic that estimates scale reliability based on correlation 
between items. It is the most commonly reported reliability 
estimate in healthcare for multiple-item scales [52]. It was 
also used to test the reliability of the UCLA-PCI during 
tool development [10] and therefore it is reported here. It 
is important to acknowledge that Cronbach’s alpha usually 
underestimates the reliability (provides a very conserva-
tive lower bound of the estimate). Other statistics such as 
Lambda2 [53] or greatest lower bound (glb) [54] are avail-
able and provide more accurate estimate (higher value of 
the lower bound) of the true reliability [55, 56]. In addi-
tion, Cronbach’s alpha does not reflect the complexity (in 
relation to factorial dimensionality) of the scale, or in other 
words, whether the items in the scale measure one or more 
related constructs. Factor analysis can be used to explore 
this [21]. Cronbach’s alpha also does not inform whether 
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the scale measures the construct that it was developed to 
measure, e.g. whether the urinary function scale measures 
urinary function or another health-related issue. However, 
because testing the dimensionality or validity of the urinary 
function scale was not the aim of these analyses, we report 
Cronbach’s alpha with alpha’s standard error (ASE) [57] to 
explore the reliability of the scale in the MRC RT01 dataset 
and to analyse the contribution of the five items in assess-
ing the underlying health concern (urinary function). This 
is to investigate whether scale reliability is a sample spe-
cific concept and whether the reliability estimate measured 
with statistics such as Cronbach’s alpha reflects a general 
reliability of the tool or rather the reliability in a specific 
population. Alpha ≥ 0.7 was used as a cut-off value for the 
acceptable reliability of a scale [58]. Each item was tested 
by calculating the scale alpha without the tested item, and 
by calculating the correlation of each item with the scale 
(not corrected and corrected for the item). This was done to 
measure the relatedness of each item with the scale and to 
explore whether the item should be included in the scale in 
the MRC RT01 dataset.
Predictive value of early urinary cluster and early 
urinary function scale
The power to predict late urinary symptoms by the early 
clusters (data were summarised according to clusters) was 
tested and compared to the scales (data were summarised 
according to item grouping outlined by the original scales). 
The analysis was performed with the receiver operating 
characteristic (ROC) curve analysis for six points in time 
(pre-hormone therapy, pre-radiotherapy, week 10, month 6, 
12 and 18). The specificity and sensitivity in predicting late 
urinary symptoms was calculated and models evaluated 
with the area under the curve (AUC) values. All the analy-
ses were performed with R version 3.0.2 (R Foundation for 
Statistical Computing, Vienna, Austria).
Results
Prevalence of urinary symptoms
Baseline characteristics of the MRC RT01 study partici-
pants are presented in Table  1 and are reported in more 
detail elsewhere [30]. The time profiles of mean scores of 
the urinary function scale items with the 95% confidence 
intervals (Fig. 1) show that the prevalence of different uri-
nary symptoms varied significantly over time. Items such 
as “Number of pads” and “Urinary leak interfering with 
sex” were rarely reported and average scores were close to 
100. Only 1% (pre-radiotherapy and pre-hormone therapy) 
to 4% (week 10 and year 5) of patients reported using any 
pads, and only 4% (month 6) to 8% (week 10) reported 
“Urinary leak interfering with sex” (Table 2). The remain-
ing three symptoms of the Urinary Function Scale were sig-
nificantly more prevalent (Fig. 1). Some level (score < 100) 
of “Urinary leak”, “Urinary control” and “Dripping/wet-
ting” was reported on average by 32% (28.3% year 1 to 
36.0% year 5), 33% (29.0% year 1 to 39.8% week 10) and 
27% of patients (23.7% year 1 to 31.5% week 10), respec-
tively (Table 2). From those three symptoms, the mean val-
ues of “urinary leak” were the lowest over time (76.6 week 
10 to 80.9 pre-radiotherapy), showing this symptom had 
the worst outcome. More patients reported “urinary bother” 
(70.6% week 10 to 33.6% year 1) than any other symptom 
in the Domain. This symptom also had the worst mean 
scores before and during treatment (Fig. 1). It improved by 
month 6 and remained higher than baseline levels through-
out follow-up.
A ceiling effect (a large proportion (>15%) of patients 
reporting a maximum score [59–61]) was observed for all 
of the six items in the Domain. Symptoms were most prev-
alent in week 10 before the acute reaction to radiotherapy 
Table 1  Patient baseline characteristics
Characteristic
Treatment, n (%)
 Standard 421 (50)
 Escalated 422 (50)
Age (years)
 Mean (SD) 67.1 (6.0)
Stage, n (%)
 T1 209 (25)
 T2 475 (56)
 T3 147 (17)
 Missing 12 (1)
Gleason score, n (%)
 2–4 70 (8)
 5–6 411 (49)
 7 191 (23)
 8–10 96 (11)
 Missing 75 (9)
Pre-hormone PSA (ng/ml)
 Mean (SD) 15.4 (9.8)
 Missing 6 (1)
Pre-existing co-morbidities, n (%)
 Diabetes 55 (6)
 Hypertension 252 (30)
 Inflammatory bowel or diverticular disease 36 (4)
 Haemorrhoids in past 12 months 89 (11)
Previous pelvic surgery, n (%) 48 (6)
Previous TURP, n (%) 100 (12)
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had settled. However, even in week 10, the percentage 
of patients reporting no symptoms (a score equal to 100) 
ranged from 27.5% for “urinary bother”, through to 58.1% 
for “urinary control” and up to even 93.0% for “number 
of pads”. Urinary symptoms were present in 39% of 725 
patients at year 3 as reported by clinicians with LENT/
SOM. This was comparable to urinary dysfunction reported 
by patients with UCLA-PCI. In year 3, 33.1, 33.0, 25.5 and 
36.3% of patients reported experiencing “urinary leak”, 
“urinary control”, “dripping/wetting” and “urinary bother”, 
respectively. However, only 2.4 and 6.0% of patients 
reported using pads or “Urinary leak interfering with sex” 
in year 3.
Symptom clusters
The analysis of symptom clusters identified 2 clusters with 
3 or more symptoms (urinary and sexual). Bowel Cluster 
was not present. The symptom clusters were relatively sta-
ble over time, and core symptoms were present across time. 
However, cluster membership was different to that repre-
sented by the scales of the UCLA-PCI. The Urinary Cluster 
consisted of three symptoms (“urinary leak”, “urinary con-
trol” and “dripping/wetting”) out of the five urinary func-
tion scale items (see Appendix, Fig. 4). The remaining two 
symptoms (“number of pads” and “urinary leak interfer-
ing with sex”) did not exhibit high enough correlations to 
be included in the urinary cluster. The sexual cluster con-
sisted of five core symptoms (“erection ability”, “orgasm 
ability”, “quality of erections”, “frequency of erections” 
and “overall sexual function”). Out of the remaining three 
items, two (“sexual desire” and “awoke with an erection”) 
were intermittently present in the sexual cluster over time, 
and one item (“Intercourse”) did not appear in the cluster 
at any point in time. The correlation of bowel symptoms in 
the bowel function scale was not strong enough to form a 
cluster at any point in time.
Correlation and scale reliability
We analysed Spearman’s correlation of “number of pads” 
and “urinary leak interfering with sex” with the urinary 
cluster symptoms (Table 3). It emerged that the correlation 
of “number of pads” with the three urinary cluster symp-
toms ranged from 0.089 to 0.333, and the correlation of 
“urinary leak interfering with sex” ranged from 0.249 to 
0.459. These low correlation values led to the exclusion of 
these items from the urinary cluster. Cronbach’s alpha was 
>0.7 for the urinary function scale at each point in time 
which indicated reliability of the scale. However, detailed 
analysis (Table 4) has shown that excluding the “number of 
pads” item would increase Cronbach’s alpha at all points in 
time. Dropping “urinary leak interfering with sex” from the 
scale did not decrease Cronbach’s alpha either (apart from 
pre-radiotherapy). It is also worth observing that excluding 
any of the urinary cluster symptoms from the urinary func-
tion scale led to a decrease in alpha below the acceptable 
value of 0.7 at all points in time apart from week 10. The 
correlation of “number of pads” and “urinary leak inter-
fering with sex” with the urinary function scale showed 
(similarly to Spearman’s correlation analysis) low correla-
tion which ranged from 0.143 to 0.358 for the “number of 
pads” and 0.330 to 0.439 for the “urinary leak interfering 
with sex”.
Predicting late urinary symptoms (urinary cluster 
versus urinary function scale)
The power of clusters to predict late urinary symptoms 
at year 3 was evaluated and compared to that obtained 
with UCLA-PCI scales. The results of ROC analysis are 
Fig. 1  Longitudinal profiles 
of items in the University of 
California, Los Angeles Prostate 
Cancer Index (UCLA-PCI), 
Urinary Domain of Health
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Table 2  Prevalence of Urinary 
Domain items of the University 
of California, Los Angeles 
Prostate Cancer Index (UCLA-
PCI)
Point in time and score Ur. leak Ur. contr Drip/wet Pad no. Interf. sex Ur. bother
Pre-hormone therapy (N = 578)
 Mean (SD) 80.7 (33.3) 87.8 (18.6) 90.8 (17.3) 99.2 (8.1) 97.5 (12.8) 77.7 (25.6)
 100—no symptom, n (%) 403 (69.7) 382 (66.1) 413 (71.5) 566 (97.9) 504 (87.2) 265 (45.8)
 >0 and <100, n (%) 117 (20.2) 188 (32.5) 155 (26.8) 3 (0.5) 20 (3.5) 303 (52.5)
 0—worst symptom, n (%) 54 (9.3) 3 (0.5) 2 (0.3) 3 (0.5) 5 (0.9) 8 (1.4)
 Missing, n (%) 4 (0.7) 5 (0.9) 8 (1.4) 6 (1.0) 49 (8.5) 2 (0.3)
Pre-radiotherapy (N = 757)
 Mean (SD) 80.9 (32.2) 87.2 (19.1) 90.8 (17.4) 99.4 (6.6) 97.0 (14.6) 77.6 (26.2)
 100—no symptom, n (%) 512 (67.6) 484 (63.9) 537 (70.9) 737 (97.4) 628 (83.0) 350 (46.2)
 >0 and <100, n (%) 172 (22.7) 254 (33.5) 199 (26.3) 5 (0.7) 26 (3.4) 385 (50.8)
 0—worst symptom, n (%) 63 (8.3) 8 (1.1) 3 (0.4) 2 (0.3) 10 (1.3) 13 (1.7)
 Missing, n (%) 10 (1.3) 11 (1.5) 18 (2.4) 13 (1.7) 93 (12.3) 9 (1.2)
Week 10 (N = 738)
 Mean (SD) 76.6 (35.2) 84.3 (21.4) 87.4 (22.0) 97.8 (11.0) 93.4 (22.0) 64.1 (30.4)
 100—no symptom, n (%) 458 (62.1) 429 (58.1) 487 (66.0) 686 (93.0) 547 (74.1) 203 (27.5)
 >0 and <100, n (%) 183 (24.8) 283 (38.4) 224 (30.4) 28 (3.8) 40 (5.5) 482 (65.3)
 0—worst symptom, n (%) 81 (11.0) 10 (1.4) 8 (1.1) 2 (0.3) 20 (2.7) 39 (5.3)
 Missing, n (%) 16 (2.2) 16 (2.2) 19 (2.6) 22 (3.0) 131 (17.8) 14 (1.9)
Month 6 (N = 712)
 Mean (SD) 83.2 (29.4) 89.0 (17.0) 91.6 (16.7) 98.7 (9.1) 97.8 (12.5) 85.6 (21.8)
 100—no symptom, n (%) 484 (68.0) 472 (66.3) 508 (71.3) 665 (93.4) 579 (81.3) 420 (59.0)
 >0 and <100, n (%) 165 (23.2) 214 (30.1) 171 (24.0) 11 (1.5) 19 (2.7) 260 (36.5)
 0—worst symptom, n (%) 37 (5.2) 1 (0.1) 2 (0.3) 3 (0.4) 7 (1.0) 8 (1.1)
 Missing, n (%) 26 (3.7) 25 (3.5) 31 (4.3) 33 (4.6) 107 (15.0) 24 (3.4)
Year 1 (N = 689)
 Mean (SD) 83.9 (28.6) 89.2 (18.0) 91.6 (17.0) 99.4 (5.4) 96.6 (15.7) 87.7 (20.1)
 100—no symptom, n (%) 479 (69.5) 475 (68.9) 509 (73.9) 660 (95.8) 574 (83.3) 446 (64.7)
 >0 and <100, n (%) 161 (23.4) 196 (28.4) 162 (23.6) 8 (1.2) 26 (3.8) 229 (33.3)
 0—worst symptom, n (%) 34 (4.9) 4 (0.6) 1 (0.1) 0 (0.0) 12 (1.7) 2 (0.3)
 Missing, n (%) 15 (2.2) 14 (2.0) 17 (2.5) 21 (3.0) 77 (11.2) 12 (1.7)
Month 18 (N = 655)
 Mean (SD) 83.7 (28.2) 89.0 (17.2) 91.6 (16.3) 99.0 (7.1) 96.2 (16.5) 86.7 (20.8)
 100—no symptom, n (%) 446 (68.1) 440 (67.2) 473 (72.2) 625 (95.4) 516 (78.8) 405 (61.8)
 >0 and <100, n (%) 165 (25.2) 197 (30.1) 163 (24.9) 13 (2.0) 27 (4.1) 229 (35.0)
 0—worst symptom, n (%) 27 (4.1) 2 (0.3) 1 (0.2) 0 (0.0) 9 (1.4) 4 (0.6)
 Missing, n (%) 17 (2.6) 16 (2.4) 18 (2.7) 17 (2.6) 103 (15.7) 17 (2.6)
Year 2 (N = 645)
 Mean (SD) 83.6 (27.6) 88.2 (18.7) 91.5 (16.5) 99.1 (7.2) 96.2 (15.4) 86.4 (19.5)
 100—no symptom, n (%) 418 (64.8) 417 (64.7) 451 (69.9) 602 (93.3) 505 (78.3) 373 (57.8)
 >0 and <100, n (%) 170 (26.4) 190 (29.4) 155 (24.0) 9 (1.4) 34 (5.3) 239 (37.1)
 0—worst symptom, n (%) 26 (4.0) 4 (0.6) 2 (0.3) 1 (0.2) 8 (1.2) 2 (0.3)
 Missing, n (%) 31 (4.8) 34 (5.3) 37 (5.7) 33 (5.1) 98 (15.2) 31 (4.8)
Year 3 (N = 594)
 Mean (SD) 80.5 (30.8) 87.8 (17.8) 91.0 (17.3) 98.4 (10.6) 96.1 (16.3) 86.3 (20.4)
 100—no symptom, n (%) 374 (63.0) 373 (62.8) 410 (69.0) 552 (92.9) 474 (79.8) 353 (59.4)
 >0 and <100, n (%) 160 (26.9) 194 (32.7) 150 (25.2) 10 (1.7) 27 (4.5) 216 (36.3)
 0—worst symptom, n (%) 37 (6.2) 2 (0.3) 2 (0.3) 4 (0.7) 9 (1.5) 0 (0.0)
 Missing, n (%) 23 (3.9) 25 (4.2) 32 (5.4) 28 (4.7) 84 (14.1) 25 (4.2)
Year 4 (N = 515)
 Mean (SD) 78.3 (33.0) 86.3 (20.0) 89.8 (18.6) 98.0 (11.2) 96.2 (16.1) 85.9 (21.6)
 100—no symptom, n (%) 308 (59.8) 311 (60.4) 339 (65.8) 468 (90.9) 406 (78.8) 306 (59.4)
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presented in Fig. 2. The best predictive accuracy, with the 
highest AUC = 0.70, was recorded for the baseline cluster 
data (pre-hormone therapy). In all time points, clusters 
showed better predictive power than the original UCLA-
PCI scales. Although these differences were not found to be 
statistically significant, they were consistent over time.
Discussion
When investigating patterns of urinary function, it was evi-
dent that men rarely reported using pads or “Urinary leak 
interfering with sex”. In fact, statistically significantly more 
men reported a certain degree of “Urinary leak” than using 
pads. This may be due to the difference in the scales that 
those items are recorded on. The frequency intervals that 
these items are recorded at may be incompatible. “Number 
of pads” is reported daily, while “urinary leak” is investi-
gated weekly. The frequency for the other two items of 
the urinary cluster is not specified. “urinary control” is 
recorded as none, frequent or occasional and “Dripping/
wetting” is recorded as a magnitude of a problem within 
the last 4 weeks (see Appendix, Fig. 4).
The key strength of this study is that MRC RT01 is a 
large dataset with a long follow-up of patients. The limita-
tions of this study are the large number of drop-outs at each 
point in time and the fact that UCLA-PCI is a relatively 
old tool. However, the more recently developed expanded 
prostate cancer index composite (EPIC) instrument [11] 
(expanded from the UCLA-PCI) adapted similar scaling for 
its items so the findings of this study should still be appli-
cable. Both UCLA-PCI and EPIC have been developed for 
general use in prostate cancer patients [62, 63]. However, it 
has been shown that different treatment modalities as well 
as different patient populations (differing recruitment fac-
tors such as age or baseline characteristics) generate dif-
ferent symptom profiles or symptom prevalence [13–16]. 
Therefore, with evolving treatments and changing charac-
teristics of patient populations, study-specific approaches to 
analysing PROMs are warranted and symptom clusters can 
be used for this purpose.
N is the number of UCLA-PCI forms completed in each time point. Mean and standard deviation (SD) is 
calculated at each point in time for N patients
Table 2  (continued) Point in time and score Ur. leak Ur. contr Drip/wet Pad no. Interf. sex Ur. bother
 >0 and <100, n (%) 135 (26.2) 173 (33.6) 141 (27.4) 13 (2.5) 24 (4.7) 179 (34.7)
 0—worst symptom, n (%) 45 (8.7) 4 (0.8) 5 (1.0) 3 (0.6) 8 (1.6) 3 (0.6)
 Missing, n (%) 27 (5.2) 27 (5.2) 30 (5.8) 31 (6.0) 77 (15.0) 27 (5.2)
Year 5 (N = 425)
 Mean (SD) 77.5 (33.2) 85.5 (20.2) 89.5 (18.5) 97.6 (11.2) 96.2 (16.1) 84.9 (22.4)
 100—no symptom, n (%) 252 (59.3) 247 (58.1) 279 (65.6) 386 (90.8) 331 (77.9) 243 (57.2)
 >0 and <100, n (%) 118 (27.8) 151 (35.5) 122 (28.7) 17 (4.0) 19 (4.4) 157 (37.0)
 0—worst symptom, n (%) 35 (8.2) 4 (0.9) 2 (0.5) 1 (0.2) 6 (1.4) 5 (1.2)
 Missing, n (%) 20 (4.7) 23 (5.4) 22 (5.2) 21 (4.9) 69 (16.2) 20 (4.7)
Table 3  correlation analysis for the items included in the Urinary Domain of health of the University of California, Los Angeles Prostate Can-
cer Index (UCLA-PCI)
Mean correlations over time calculated using Fisher Z transform. Ranges over time are shown in brackets
Urinary leak Urinary control Number of pads Dripping/wetting Urinary leak inter-
fering with sex
Urinary bother
Urinary leak 1.00
Urinary control 0.753 (0.700–0.809) 1.00
Number of pads 0.214 (0.104–0.300) 0.202 (0.126–0.285) 1.00
Dripping/wetting 0.698 (0.644–0.746) 0.694 (0.653–0.734) 0.209 (0.089–0.333) 1.00
Urinary leak 
interfering with 
sex
0.326 (0.249–0.366) 0.306 (0.267–0.371) 0.200 (0.118–0.263) 0.389 (0.258–0.459) 1.00
Urinary bother 0.505 (0.389–0.594) 0.549 (0.464–0.630) 0.168 (0.046–0.319) 0.527 (0.384–0.599) 0.271 (0.191–0.370) 1.00
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Cluster analysis provide a study-specific approach to 
summarising PROMs data and to exploring trends for uti-
lisation of PROMs in clinical practice [64]. This concept is 
illustrated in Fig. 3 using the UCLA-PCI Urinary Domain. 
The two mechanisms of symptoms grouping are illus-
trated (cluster analysis is used to revise scale membership). 
Table 4  Cronbach’s alpha 
reliability analysis to evaluate 
the internal structure of the 
Urinary Function Scale of the 
University of California, Los 
Angeles Prostate Cancer Index 
(UCLA-PCI). Alpha ≥ 0.7 
was used as a cut-off for the 
acceptable internal consistency
Each item was tested by calculating (a) scale alpha ± alpha’s standard error (ASE) without the tested item 
(column 1), (b) not corrected correlation of an item with the scale (column 2) and (c) correlation of an item 
with the scale corrected for the item (column 3)
Scale alpha = 0.721 ± 0.030 Alpha without the item Correlation 
with the scale
Correlation with the 
scale without the 
item
Pre-hormone therapy
 Urinary leak 0.604 ± 0.038 0.800 0.688
 Urinary control 0.614 ± 0.039 0.785 0.685
 Number of pads 0.775 ± 0.032 0.474 0.205
 Dripping/wetting 0.608 ± 0.039 0.795 0.698
 Urinary leak interfering with sex 0.727 ± 0.033 0.584 0.330
Pre-radiotherapy
 Urinary leak 0.624 ± 0.032 0.790 0.683
 Urinary control 0.625 ± 0.034 0.789 0.701
 Number of pads 0.802 ± 0.027 0.426 0.143
 Dripping/wetting 0.613 ± 0.033 0.807 0.709
 Urinary leak interfering with sex 0.705 ± 0.029 0.651 0.414
Week 10
 Urinary leak 0.705 ± 0.031 0.826 0.717
 Urinary control 0.724 ± 0.031 0.791 0.680
 Number of pads 0.815 ± 0.026 0.583 0.358
 Dripping/wetting 0.695 ± 0.032 0.844 0.750
 Urinary leak interfering with sex 0.792 ± 0.027 0.642 0.439
Month 6
 Urinary leak 0.658 ± 0.033 0.806 0.710
 Urinary control 0.670 ± 0.034 0.785 0.702
 Number of pads 0.796 ± 0.027 0.520 0.253
 Dripping/wetting 0.641 ± 0.034 0.833 0.744
 Urinary leak interfering with sex 0.759 ± 0.028 0.610 0.365
Year 1
 Urinary leak 0.661 ± 0.033 0.829 0.739
 Urinary control 0.681 ± 0.034 0.796 0.739
 Number of pads 0.813 ± 0.027 0.507 0.255
 Dripping/wetting 0.658 ± 0.033 0.835 0.738
 Urinary leak interfering with sex 0.766 ± 0.028 0.624 0.386
Month 18
 Urinary leak 0.650 ± 0.035 0.832 0.714
 Urinary control 0.677 ± 0.035 0.786 0.685
 Number of pads 0.797 ± 0.029 0.532 0.296
 Dripping/wetting 0.655 ± 0.035 0.824 0.712
 Urinary leak interfering with sex 0.771 ± 0.030 0.596 0.380
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Symptom clusters contribute to the interpretation of 
PROMs data by grouping symptoms according to their 
prevalence and excluding items that are not representative 
of the same underlying health concern. “Urinary leak inter-
fering with sex” has been shown not to be related to the 
other urinary function scale items. This item represents a 
Fig. 2  ROC curve analysis 
comparing predictive power 
of clusters to domains of 
the University of California, 
Los Angeles Prostate Cancer 
Index (UCLA-PCI). A binary 
item (yes/no) representing 
the presence or absence of 
urinary symptoms at year 3 
post-radiotherapy was used as 
an endpoint. It was measured 
with the Late Effects on Normal 
Tissue: Subjective, Objective, 
Management tool (LENT/
SOM), bladder/urethra section
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link between sexual activity and urinary function. However, 
it did not cluster with the three urinary cluster symptoms. 
This may be due to the low prevalence of this item. Patients 
reported it rarely. Additionally, the analysis of missing val-
ues has shown that this item was left unanswered more 
often than any other urinary domain questions (Table  2). 
Both low prevalence and high degree of missingness, may 
reflect low levels of sexual activity within patients in the 
analysed study [14]. This item may be of lower relevance 
than other items and may not reflect urinary function. 
Therefore, including it in a summative score may lead to 
the loss of significant information.
Another implication for PROMs data analysis is 
observed for all the items in the urinary domain signifi-
cant ceiling effect. This ceiling effect may be due to inad-
equate sensitivity of the scales adapted for each item. It 
may be that the scale levels (or ranges of scores) are not 
sensitive enough to capture the functional status of patients, 
and most patients score it at the upper limit of the range. 
Therefore, reporting the frequency of those items may not 
be insightful enough, and although, all the questions were 
standardised prior to analysis, a ceiling effect occurs for 
considerably more patients in the “number of pads” or “uri-
nary leak interfering with sex” than for other urinary func-
tion items. However, the observed ceiling effect may also 
be due to the large numbers of patients not experiencing 
any dysfunction. Late effects from radiotherapy have been 
shown to occur in 5–10% of prostate cancer survivors [15, 
35, 65, 66]. Nevertheless, the ceiling effect poses signifi-
cant implications for data analysis and interpretation. Issues 
such as a low variance in the recorded data or data skew-
ness due to abnormal distribution have to be accounted for 
and interpreted appropriately [67].
“Urinary bother” was the most prevalent item of the 
urinary domain. The baseline and acute scores of the “uri-
nary bother” were lower than all the urinary function items. 
This has also been observed in other studies and patients 
reported lower bother scores than they rated their func-
tional status [16, 68]. “Urinary bother” did not cluster with 
the urinary function items at any point in time and the cor-
relation was low to moderate.
Urinary function scale contains five items that were 
developed to represent urinary function. However, two of 
the items have shown significantly lower prevalence as well 
as weak correlation compared to the remaining three items 
of the scale. Detailed correlation analysis has shown a con-
sistently low correlation of “number of pads” and “urinary 
leak interfering with sex” with the other items. It is pos-
sible that they may not measure the same underling health 
issue or may not represent the urinary function. Therefore, 
including them in the summative score may lead to a loss 
of significant information due to the ceiling effect and weak 
relationship. This was reflected in the result of the cluster 
analysis. Cluster analysis could be applied to evaluate scale 
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• dripping/wetting
• urinary control 
• dripping/wetting
• number of pads 
• urinary leak interfering with sex
symptoms (< 0.6)
• Low prevalence in the 
dataset (ceiling effect)
• Not representative of 
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• Not relevant to patients?
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• Correlation consistent 
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Fig. 3  An illustration of two mechanisms of symptom grouping and 
how symptom clusters can contribute to the interpretation of patients 
reported outcome measures (PROMs) data. Using generic scales 
of the University of California, Los Angeles Prostate Cancer Index 
(UCLA-PCI) (left) and using cluster analysis to revise scale member-
ship (right)
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membership and to explore significant factors in PROMs 
data. Symptom clusters allow for study-specific approaches 
to be incorporated into PROMs data modelling techniques. 
The analysis can be used rather than grouping items with 
the original tool’s scales. Cronbach’s alpha analysis con-
firmed the clustering results. It has shown that by excluding 
those items from the urinary function scale, the reliability 
of the scale has not been compromised. The summative 
scores of the clusters also showed better predictive power 
than the summative scores obtained from the scales. The 
difference is not statistically significant but is consistent 
and is probably due to poorly correlated items included in 
the summative scores. Poor correlation, low variance as 
well as the degree of negative skewness should be inves-
tigated for each study when analysing PROMs. This may 
result in different groups of items or in the exclusion of 
some items from the summative scores. This may also 
advance PROMs data analysis and lead to extraction of 
more relevant information. It should be recognised that this 
study is based on an old tool (UCLA-PCI) that has largely 
been replaced with the EPIC [11]. However, because EPIC 
has been developed based on UCLA-PCI, the results of this 
study are still highly relevant. EPIC, similarly to UCLA-
PCI (and other instruments used to investigate function and 
HRQOL in cancer patients), is a tool that uses multiple-
item scales and requires calculation of composite scores to 
extract and analyse PROMs data.
Conclusions
This study adds to knowledge on how cluster analysis can 
help to interpret and utilise PROMs. Scale membership 
was reviewed by cluster analysis, and the reliability of the 
Urinary Function Scale was evaluated. The approach of 
symptom clusters allows for a method of study-specific 
item grouping that can be used to calculate surrogate 
scores that simplify PROMs. Using summary scores of 
related items, rather than analysing symptoms in isolation, 
is essential because closely related variables exhibit a high 
degree of collinearity, which has implications for statisti-
cal approaches. This is also important in clinical decision 
making, and better health outcomes and HRQOL have been 
achieved when related symptoms were clinically considered 
and managed together [24, 25]. We recommend that when 
summarising and modelling PROMs data in clinical trials, 
scales membership should be reviewed. This is because the 
grouping of symptoms may vary for different studies, treat-
ments and patient populations. Symptom clusters can be 
used for this purpose. They can be calculated individually 
for each study, and this can facilitate a study-specific rather 
than generic method of grouping items. This approach is 
more meaningful for the purpose of symptom management.
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